MX9201110A - Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados. - Google Patents

Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados.

Info

Publication number
MX9201110A
MX9201110A MX9201110A MX9201110A MX9201110A MX 9201110 A MX9201110 A MX 9201110A MX 9201110 A MX9201110 A MX 9201110A MX 9201110 A MX9201110 A MX 9201110A MX 9201110 A MX9201110 A MX 9201110A
Authority
MX
Mexico
Prior art keywords
treatment
sufferings
hypoglycemia
composition
diabetes mellitus
Prior art date
Application number
MX9201110A
Other languages
English (en)
Inventor
Kevin Beaumont Andrew A Young
Original Assignee
Amylin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/670,231 external-priority patent/US5264372A/en
Application filed by Amylin Corp filed Critical Amylin Corp
Publication of MX9201110A publication Critical patent/MX9201110A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan métodos para el tratamiento de diabetes y otros estados que requieren de insulina, administrando insulina y una calcitonina con o sin amilina, y los métodos para el tratamiento de estados hipoglucémicos administrando una calcitonina sola o en combinación con glucagon y/o una amilina y composiciones relacionadas.
MX9201110A 1991-03-15 1992-03-13 Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados. MX9201110A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/670,231 US5264372A (en) 1991-03-15 1991-03-15 Receptor-based screening methods for amylin agonists and antagonists
US70499591A 1991-05-24 1991-05-24
US07/774,411 US5321008A (en) 1991-01-10 1991-10-10 Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions

Publications (1)

Publication Number Publication Date
MX9201110A true MX9201110A (es) 1993-07-01

Family

ID=27418205

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9201110A MX9201110A (es) 1991-03-15 1992-03-13 Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados.

Country Status (11)

Country Link
US (2) US5321008A (es)
EP (1) EP0533898B1 (es)
JP (1) JPH05507943A (es)
AT (1) ATE170401T1 (es)
AU (1) AU648895B2 (es)
CA (1) CA2082928C (es)
DE (1) DE69226835T2 (es)
DK (1) DK0533898T3 (es)
ES (1) ES2122995T3 (es)
MX (1) MX9201110A (es)
WO (1) WO1992016222A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
JP2818296B2 (ja) * 1991-01-10 1998-10-30 アミリン・ファーマシューティカルズ・インコーポレイテッド アミリン活性検定
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
DK1044015T3 (da) * 1998-01-09 2008-12-08 Amylin Pharmaceuticals Inc Formuleringer med amylinagonistpeptider og insulin
WO1999040928A1 (en) 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Novel mixed amylin activity compounds
US6936584B1 (en) 1998-02-13 2005-08-30 Amylin Pharmaceuticals, Inc. Mixed amylin activity compounds
JP4659336B2 (ja) * 2000-10-26 2011-03-30 アルザ・コーポレーシヨン 被覆された微細突出物を有する経皮的薬剤配達装置
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004060387A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
KR20070029276A (ko) * 2004-06-29 2007-03-13 디오벡스, 인코포레이티드 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
WO2009156473A1 (en) * 2008-06-25 2009-12-30 Novo Nordisk A/S Derivatised hybrid peptides of amylin and salmon calcitonin
MX2011009559A (es) * 2009-03-12 2012-01-12 Nordic Bioscience As Tratamiento de la diabetes y el sindrome metabolico.
CN117653715A (zh) 2017-02-03 2024-03-08 范德比尔特大学 用于治疗糖尿病的系统、组合物和方法
CA3116023A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3171774D1 (en) * 1980-03-31 1985-09-19 Teijin Ltd Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
WO1989006135A1 (en) * 1988-01-11 1989-07-13 Amylin Corporation Treatment of type 2 diabetes mellitus
ES2080802T3 (es) * 1989-07-10 1996-02-16 Amylin Pharmaceuticals Inc Uso de un antagonista de amilina en la preparacion de un medicamento para el tratamiento de la obesidad e hipertension intrinseca y desordenes asociados.

Also Published As

Publication number Publication date
EP0533898B1 (en) 1998-09-02
CA2082928A1 (en) 1992-09-16
AU1687392A (en) 1992-10-21
ES2122995T3 (es) 1999-01-01
EP0533898A1 (en) 1993-03-31
DE69226835T2 (de) 1999-01-14
DK0533898T3 (da) 1999-05-31
US5508260A (en) 1996-04-16
WO1992016222A1 (en) 1992-10-01
ATE170401T1 (de) 1998-09-15
CA2082928C (en) 2000-09-05
JPH05507943A (ja) 1993-11-11
US5321008A (en) 1994-06-14
DE69226835D1 (de) 1998-10-08
AU648895B2 (en) 1994-05-05
EP0533898A4 (en) 1993-10-13

Similar Documents

Publication Publication Date Title
MX9201110A (es) Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados.
NO940436L (no) Forlenget avgivelse av peptider
CA2373266A1 (en) Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
BRPI0409600A (pt) análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina
ATE193541T1 (de) Insulinotropes hormon
DE69942307D1 (de) N-terminal veränderte glp-1 abkömmlinge
AR012998A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente.
AU3372595A (en) Biologically active fragments of glucagon-like insulinotropic peptide
DE69327309D1 (de) Verwendung eines peptids
WO1999043705A8 (en) N-terminally truncated glp-1 derivatives
AR022368A1 (es) Procedimiento para administrar peptidos insulinotropicos
UY26483A1 (es) Activadores de la glucoquinasa transolefinica
EP2022505A3 (en) GLP-1, exendin-4, peptide analogs and uses thereof
ATE369873T1 (de) Metabolische intervention mit glp-1 oder seinen biologisch aktiven analogen zur verbesserung der funktion des ischämischen und wiederdurchbluteten gehirns
ES2334258T3 (es) Control de la glucosa en sangre en el tratamiento de la diabetes que usa la insulina administrada pulmonarmente en combinacion con la insulina basal.
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
ES2108122T3 (es) Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas.
ES2166406T3 (es) Uso de derivados de 1,5-benzodiazepina para el control del vaciado gastrico en pacientes con diabetes mellitus no dependiente de insulina.
ATE491723T1 (de) Neue verbindungen mit gemischter amylin aktivität
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
AR008025A1 (es) Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
ES2135353A1 (es) Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones.